Ocean Biomedical, Inc. financial data

Symbol
OCEA on OTC
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 15 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.76 % -36.1%
Debt-to-equity -101 % +2.3%
Return On Equity 32.42 % -16.3%
Return On Assets -2,248 % -1.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 166,010,805 shares +3.8%
Common Stock, Shares, Outstanding 166,010,805 shares +3.8%
Entity Public Float 5,473,916 USD +5,473,914.5%
Weighted Average Number of Shares Outstanding, Basic 91,024,268 shares +2.3%
Weighted Average Number of Shares Outstanding, Diluted 91,024,268 shares +2.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 18,000 USD -30.8%
General and Administrative Expense 4,143,000 USD -18.4%
Operating Income (Loss) -4,161,000 USD +23.3%
Nonoperating Income (Expense) -26,558,000 USD -10.9%
Net Income (Loss) Attributable to Parent -30,719,000 USD -4.6%
Earnings Per Share, Basic -1 USD/shares +6.2%
Earnings Per Share, Diluted -1 USD/shares +6.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 1,492,000 USD -17.1%
Assets 1,582,000 USD -46.3%
Accounts Payable, Current 16,387,000 USD -2.9%
Accrued Liabilities, Current 946,000 USD +1.1%
Liabilities, Current 26,568,000 USD -11.8%
Liabilities 93,981,000 USD +19.4%
Retained Earnings (Accumulated Deficit) -213,775,000 USD -16.8%
Stockholders' Equity Attributable to Parent -92,399,000 USD -21.9%
Liabilities and Equity 1,582,000 USD -46.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -356,000 USD +26.6%
Net Cash Provided by (Used in) Financing Activities 909,000 USD
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 166,010,805 shares +3.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 553,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 800,000 USD
Deferred Tax Assets, Valuation Allowance 22,592,000 USD +8.8%
Deferred Tax Assets, Gross 22,592,000 USD +8.8%
Deferred Tax Assets, Operating Loss Carryforwards 7,642,000 USD +28.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares +7%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 121,376,000 USD +13.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 745,000 USD 0%
Interest Expense 50,000 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%